Myelodysplastic syndromes (MDS) occurring in Agent Orange exposed individuals carry a mutational spectrum similar to that of de novo MDS

Adam S. SperlingDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; ;Broad Institute of MIT and Harvard, Cambridge, MA, USAView further author information

Matthew LeventhalBroad Institute of MIT and Harvard, Cambridge, MA, USAView further author information

Christopher J. GibsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; View further author information

Benjamin L. EbertDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; ;Broad Institute of MIT and Harvard, Cambridge, MA, USAView further author information

David P. SteensmaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Correspondence[email protected]
View further author information

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors thank Maxwell Teschke for website design assistance and administrative support for sample collection, John Huber (retired CEO of Aplastic Anemia & MDS International Foundation) for project support, and Robert Macfarlane for increasing awareness of the project among the Vietnam-era veteran community.

Disclosure statement

BLE has received consulting fees from Grail and research support from Celgene and Deerfield. DPS has received research support from Celgene, Aprea, and H3 Biosciences, has served on an independent data monitoring committee for Onconova and Takeda, and has received consulting fees from Sensei, Summer Road, and Janssen.

Additional information

Funding

This study was funded by a grant from the Aplastic Anemia & MDS International Foundation, Bethesda, Maryland and the Edward P. Evans Foundation.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Myelodysplastic syndromes (MDS) occurring in Agent Orange exposed individuals carry a mutational spectrum similar to that of de novo MDS

Information for

Open access

Opportunities

Help and information

Myelodysplastic syndromes (MDS) occurring in Agent Orange exposed individuals carry a mutational spectrum similar to that of de novo MDS

Acknowledgements

Disclosure statement

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature